All companies
Progyny Inc. logo

What smart money is saying about Progyny Inc.United States flag

PGNY · Healthcare · Medical - Healthcare Plans · Market cap $2.04B

1 fund in our archive has pitched Progyny Inc. — most recently Buffalo funds Mid Cap Growth Fund in June 2026.

Company profile

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Get an email when a fund writes about it

Summarize with Warren AI
2
Reported positions
0
Bought
0
Sold
2
Letters

Position history

Every position in Progyny Inc. on record in the archive was reported in Q2 2026, across 2 fund letters, with no move described.

Fund letters reporting a position in Progyny Inc., by quarter
QuarterLettersBoughtSoldTheses
Q2 20262001

Fund activity · 2 positions

  • Listed in Signia Capital Management Small Cap Value Strategy’s reported holdings.

    Progyny Inc.
  • Progyny Inc. (PGNY) is a leading fertility and family-building benefits management provider for self-insured employers. The company demonstrates best-in-class fertility outcomes and is positioned to benefit from the societal trend towards later- in-life pregnancies in developed countries. They enjoy an asset-light, cash-generative business model along with strong net-cash balance sheet, undemanding valuation multiple, and are rapidly shrinking the share count through repurchases. The company reported earnings that beat investor expectations in the quarter and the stock outperformed but remained a compelling investment opportunity in our view.
    Progyny Inc.

Fund coverage · 1 thesis

Read every full thesis on Progyny Inc.

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger